Anti-LRRK2, Rabbit-Poly <Anti-Leucine-Rich Repeat Kinase 2>

データシート

• 商品コード：NB300-268
• メーカー：NOV
• 包装：0.1ml
• 価格： ¥91,000
• 在庫：無(未発注)

マイリストに追加 マイリストに追加済

• No.： 1
• 文献情報：
  Miklossy J et al. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 2006 Oct;65(10):953-63
  Miklossy J et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 2
• 文献情報：
  Melrose HL et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007 Jul;147(4):1047-58
  Melrose HL et al
  2007/01/01
  
• 備考：
  Western Blot, Immunohistochemistry
• 参照：
  

• No.： 3
• 文献情報：
  Alegre-Abarrategui J et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009 Nov;18(21):4022-34
  Alegre-Abarrategui J et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 4
• 文献情報：
  Venderova K et al. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson&quot;s disease. Hum. Mol. Genet. 2009 Nov;18(22):4390-404
  Venderova K et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 5
• 文献情報：
  Liu Z et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 2011 Nov;12(11):1063-70
  Liu Z et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 6
• 文献情報：
  Ito G et al. Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem. J. 2012 Feb;441(3):987-94
  Ito G et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 7
• 文献情報：
  Saha S et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 2009 Jul;29(29):9210-8
  Saha S et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 8
• 文献情報：
  Hatano T et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 2007 Mar;16(6):678-90
  Hatano T et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 9
• 文献情報：
  Santpere G et al. LRRK2 and neurodegeneration. Acta Neuropathol. 2009 Mar;117(3):227-46
  Santpere G et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 10
• 文献情報：
  Hakimi M et al. Parkinson&quot;s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011 May;118(5):795-808
  Hakimi M et al
  2011/01/01
  
• 備考：
  Applications: WB, Species: Human, Mouse
• 参照：
  

• No.： 11
• 文献情報：
  Hermann A et al. Reduced LRRK2-positive neurons in the striatum of Parkinson’s disease patients hypothesize a retrograde disease mechanism? . Basal Ganglia http://dx.doi.org/10.1016/j.baga.2012.04.030. 2012. (IHC and IHC, IF, Human)
  
  
• 備考：
  Species: Human, Applications: IHC and IHC, IF
• 参照：
  

• No.： 12
• 文献情報：
  Pandey N et al. Sequences Located within the N-Terminus of the PD-Linked LRRK2 Lead to Increased Aggregation and Attenuation of 6-Hydroxydopamine-Induced Cell Death. PLoS ONE 2012;7(9):e45149
  Pandey N et al
  2012/01/01
  
• 備考：
  Applications: WB
• 参照：
  

• No.： 13
• 文献情報：
  Yao C et al. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson&quot;s disease. Neurobiol. Dis. 2010 Oct;40(1):73-81
  Yao C et al
  2010/01/01
  
• 備考：
  Species: C. elegans, Applications: IHC, ICC/IF, WB
• 参照：
  

• No.： 14
• 文献情報：
  Marker DF et al. LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J Neuroinflammation 2012;9:261
  Marker DF et al
  2012/01/01
  
• 備考：
  Species: Mouse, Applications: ICC/IF
• 参照：
  

• No.： 15
• 文献情報：
  Qing H et al. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun. 2009 Dec;390(4):1229-34
  Qing H et al
  2009/01/01
  
• 備考：
  Species: Human, Applications: IHC, ICC/IF
• 参照：
  

• No.： 16
• 文献情報：
  Kamikawaji S et al. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009 Nov;48(46):10963-75
  Kamikawaji S et al
  2009/01/01
  
• 備考：
  Species: Human, Moth, Applications: IP, WB
• 参照：
  

• No.： 17
• 文献情報：
  Greggio E et al. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J. Neurochem. 2007 Jul;102(1):93-102
  Greggio E et al
  2007/01/01
  
• 備考：
  Species: Human, Applications: WB
• 参照：
  

• No.： 18
• 文献情報：
  Kamikawaji S et al. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation. Biochemistry 2013 Sep;52(35):6052-62
  Kamikawaji S et al
  2013/01/01
  
• 備考：
  Species: Human, Applications: WB
• 参照：
  

• No.： 19
• 文献情報：
  Sekigawa A et al. Distinct mechanisms of axonal globule formation in mice expressing human wild type &#x3B1;-synuclein or dementia with Lewy bodies-linked P123H &#x3B2;-synuclein. Mol Brain 2012;5:34
  Sekigawa A et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 20
• 文献情報：
  Angeles DC et al. Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum. Mol. Genet. 2014 Jun;23(12):3157-65
  Angeles DC et al
  2014/01/01
  
• 備考：
  Species: Human, Applications: WB
• 参照：
  

• No.： 21
• 文献情報：
  Chan SL et al. MAP1B rescues LRRK2 mutant-mediated cytotoxicity. Mol Brain 2014;7:29
  Chan SL et al
  2014/01/01
  
• 備考：
  Species: Human, Applications: ICC/IF, WB
• 参照：
  

• No.： 22
• 文献情報：
  Gaig C et al. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J. Neurol. Sci. 2008 Jul;270(1-2):94-8
  Gaig C et al
  2008/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 23
• 文献情報：
  Waxman EA et al. Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J. Neuropathol. Exp. Neurol. 2009 Jul;68(7):785-96
  Waxman EA et al
  2009/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 24
• 文献情報：
  Alegre-Abarrategui J et al. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson&quot;s disease. Neuropathol. Appl. Neurobiol. 2007 Oct;
  Alegre-Abarrategui J et al
  2007/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 25
• 文献情報：
  Ludolph AC et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol. 2009 Mar;16(3):297-309
  Ludolph AC et al
  2009/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 26
• 文献情報：
  Ito G et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson&quot;s disease. Biochemistry 2007 Feb;46(5):1380-8
  Ito G et al
  2007/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 27
• 文献情報：
  Miklossy J et al. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol. 2007 Sep;114(3):243-54
  Miklossy J et al
  2007/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 28
• 文献情報：
  Nucifora FC et al. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nat Commun 2016;7:11792
  Nucifora FC et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 29
• 文献情報：
  Sheng D et al. Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet. 2010 Apr;6(4):e1000914
  Sheng D et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 30
• 文献情報：
  Higashi S et al. Localization of Parkinson&quot;s disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007 Jun;1155:208-19
  Higashi S et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 31
• 文献情報：
  Zhu X et al. LRRK2 in Parkinson&quot;s disease and dementia with Lewy bodies. Mol Neurodegener 2006;1:17
  Zhu X et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 32
• 文献情報：
  Zhu X et al. LRRK2 protein is a component of Lewy bodies. Ann. Neurol. 2006 Nov;60(5):617-8; author reply 618-9
  Zhu X et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 33
• 文献情報：
  Bliederhaeuser C et al. LRRK2 contributes to monocyte dysregulation in Parkinson&quot;s disease. Acta Neuropathol Commun 2016 11;4(1):123
  Bliederhaeuser C et al
  2016/01/01
  
• 備考：
  Species: Human, Applications: FLOW
• 参照：
  

• No.： 34
• 文献情報：
  Lim J et al. LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT_1A Receptor Upregulation in Mice. J. Neurosci. 2018 Feb;38(7):1611-1621
  Lim J et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 35
• 文献情報：
  Chen S et al. Generation of two LRRK2 homozygous knockout human induced pluripotent stem cell lines using CRISPR/Cas9. Stem Cell Res 2020 05;45:101804
  Chen S et al
  2020/01/01
  
• 備考：
  
• 参照：
  

• No.： 36
• 文献情報：
  Hsieh CH et al. Miro1 Marks Parkinson&quot;s Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson&quot;s Models. Cell Metab. 2019 12;30(6):1131-1140.e7
  Hsieh CH et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 37
• 文献情報：
  Chen ZC et al. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson&quot;s disease. Sci Signal 2017 Jul;10(488)
  Chen ZC et al
  2017/01/01
  
• 備考：
  
• 参照：